Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Third Quarter 2022 Financial Results and Provide Corporate Update

Rhea-AI Summary

Xenon Pharmaceuticals (Nasdaq:XENE) announced it will release its third quarter 2022 financial results on November 8, 2022, after U.S. markets close. The company is focused on developing innovative therapies for neurological disorders, particularly epilepsy. A live conference call and audio webcast will take place at 4:30 PM ET on the same day. Investors can register for participation to receive dial-in details. Xenon is committed to addressing high unmet medical needs in the neurology sector.

Positive

• Xenon focuses on developing innovative therapeutics for neurological disorders.
• Company emphasizes addressing high unmet medical needs in epilepsy.

Negative

• None.

BURNABY, British Columbia, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its third quarter 2022 financial and operating results after the close of U.S. financial markets on Tuesday, November 8, 2022.

Conference Call/Webcast Information:
Date:	Tuesday, November 8, 2022
Time:	4:30 pm Eastern Time (1:30 pm Pacific Time)
Listen-Only Audio Webcast:	https://edge.media-server.com/mmc/p/s4tct434
Live Call Participant:	Registration Link

To participate in the live call, please register using the following link (also noted above) to receive dial-in details and a unique PIN code: Register and receive dial-in details. The audio webcast will also be broadcast live on the “Investors” section of Xenon's website at investor.xenon-pharma.com and posted for replay following the event. The above-listed dates and times are subject to change.

About Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit www.xenon-pharma.com.

“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.

Investor/Media Contact:
Jodi Regts
Xenon Pharmaceuticals Inc.
Phone: 604.484.3353
Email: investors@xenon-pharma.com

FAQ

When will Xenon Pharmaceuticals report its Q3 2022 financial results?

Xenon Pharmaceuticals will report its Q3 2022 financial results on November 8, 2022.

What time is the Xenon Pharmaceuticals conference call for Q3 2022 results?

The conference call will be at 4:30 PM ET on November 8, 2022.

How can I participate in the Xenon Pharmaceuticals Q3 2022 results call?

Participants can register using the provided link to receive dial-in details for the call.

What is the focus of Xenon Pharmaceuticals' product pipeline?

Xenon Pharmaceuticals focuses on developing therapies for neurological disorders, with an emphasis on epilepsy.